COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?

Javelot, Hervé; El-Hage, Wissam; Meyer, Guillaume; Becker, Guillaume; Michel, Bruno; Hingray, Coraline

Javelot, Hervé; El-Hage, Wissam; Meyer, Guillaume; Becker, Guillaume; Michel, Bruno; Hingray, Coraline.

Javelot H; Clinical Pharmacy Service, EPSAN, Brumath, France.
El-Hage W; Laboratoire de Toxicologie et Pharmacologie Neuro Cardiovasculaire, Université de Strasbourg, Strasbourg, France.
Meyer G; UMR 1253, iBrain, Université de Tours, CHRU de Tours, INSERM, Tours, France.
Becker G; CentreExpert Dépression Résistante, Fondation FondaMental, Tours, France.
Michel B; Clinical Pharmacy Service, EPSAN, Brumath, France.
Hingray C; Clinical Pharmacy Service, CHU, Strasbourg, France.

Br J Clin Pharmacol ; 86(6): 1176-1177, 2020 06.

Article in English | MEDLINE | ID: covidwho-143891

Subject(s)

Azithromycin/administration & dosage; Chloroquine/administration & dosage; Coronavirus Infections/drug therapy; Hydroxychloroquine/administration & dosage; Pneumonia, Viral/drug therapy; Azithromycin/adverse effects; COVID-19; Chloroquine/adverse effects; Coronavirus Infections/epidemiology; Drug Therapy, Combination; Humans; Hydroxychloroquine/adverse effects; Long QT Syndrome/chemically induced; Long QT Syndrome/epidemiology; Mental Disorders/complications; Pandemics; Pneumonia, Viral/epidemiology; Risk Factors

Keywords

COVID-19; QT prolongation; azithromycin; hydroxychloroquine

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Chloroquine / Coronavirus Infections / Azithromycin / Hydroxychloroquine Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Br J Clin Pharmacol Year: 2020 Document Type: Article Affiliation country: Bcp.14335

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google